Jagsonpal Pharmaceuticals share news, announcements and annual reports
NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap
Jagsonpal Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹216.09down ₹5.85 (2.64%)BSE ₹216.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹221.94.
30 Oct: open ₹222.00, high ₹226.64, low ₹212.58
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,427 Cr1,360th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 31.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 5.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.85%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 71,54749.3% delivered
Jagsonpal Pharmaceuticals board meetings
121 filed, newest first. Page 2 of 3.
Nov 2019
Aug 2019
13 Aug · Board meeting
1 Aug · Board meeting
May 2019
28 May · Board meeting
Feb 2019
13 Feb · Board meeting
4 Feb · Board meeting
Nov 2018
14 Nov · Board meeting
Aug 2018
9 Aug · Board meeting
1 Aug · Board meeting
May 2018
30 May · Board meeting
17 May · Board meeting
Feb 2018
Dec 2017
4 Dec · Board meeting
Inter-alia, to consider and approve the Unaudited Financial Results (Standalone) for the second quarter ended September 30, 2017. This information is also be available on the Company's website at www.jagsonpal.com
Aug 2017
May 2017
29 May · Board meeting
19 May · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the year from April 1st, 2016 to March 31, 2017 and consider Dividend,
Feb 2017
14 Feb · Board meeting
Nov 2016
11 Nov · Board meeting
Aug 2016
12 Aug · Board meeting
May 2016
Feb 2016
17 Feb · Board meeting
13 Feb · Board meeting
Jan 2016
25 Jan · Board meeting
Nov 2015
Jul 2015
May 2015
Feb 2015
3 Feb · Board meeting
To Consider, approve and take on record the Un-audited Financial Results (provisional) of the Company for the quarter ended December 31, 2014.
Nov 2014
4 Nov · Board meeting
To Consider, approve and take on record the Un-audited Financial Results (provisional) of the Company for the quarter ended September 30, 2014.
Aug 2014
14 Aug · Board meeting
Company had informed the Exchange regarding a meeting of the Board of Directors of the Company to be held on August 14, 2014. The Company has now informed the Exchange that the aforesaid Board Meeting stand adjourned to August 21, 2014 due to want of quorum.6 Aug · Board meeting
To Consider, approve and take on record the Un-audited Financial Results (provisional) of the Company for the quarter ended June 30, 2014.
May 2014
Feb 2014
3 Feb · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended December 31, 2013.
Nov 2013
5 Nov · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended on September 30, 2013.
Aug 2013
6 Aug · Board meeting
To consider and take on record the Un-Audited financial results (Provisional) for the quarter ended June 30, 2013.
May 2013
21 May · Board meeting
To : (1) Consider and Approve the Audited Financial Results for the quarter/ year ended March 31, 2013; (2) Recommend dividend, if any, for the year ended March 31, 2013.
Feb 2013
6 Feb · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended on December 31, 2012.
Oct 2012
31 Oct · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended on September 30, 2012.
May 2012
21 May · Board meeting
To : (1) Consider and Approve the Audited Financial Results for the quarter/ year ended March 31, 2012; (2) Recommend dividend, if any, for the year ended March 31, 2012.
Feb 2012
3 Feb · Board meeting
To consider and take on record the un-audited financial results (provisional) for Quarter ended on December 31, 2011.
Nov 2011
8 Nov · Board meeting
To consider and take on record the un-audited financial results (provisional) for Quarter ended on September 30, 2011.
Aug 2011
1 Aug · Board meeting
To : (1) Consider and Approve the Audited financial results for the quarter/year ended March 31, 2011; (2) Recommend dividend, if any, for the year ended March 31, 2011; (3) Consider and take on record the Un-Audited financial results (Provisional) for the quarter ended June 30, 2011.